Discover. Innovate.
Deliver.
A clinical-stage company advancing cell and exosome therapies for debilitating neurodegenerative diseases.
- NurOwn®Phase 3b in ALS
- 4Completed ALS trials
- ExosomesPre-clinical, next generation
Our mission
Best-in-class autologous cellular therapies for neurodegenerative disease - built on NurOwn®, our MSC-NTF cell technology platform.
NurOwn technology platform
The patient's own cells. Transformed.
Autologous MSC-NTF cells, manufactured individually from each patient's bone marrow and delivered intrathecally.
Explore the science
- HarvestBone marrow from the patient
- DifferentiateInto MSC-NTF cells
- DeliverIntrathecal injection
Exosome platform
Made once, for many.
A proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids.
- AllogeneicMade once, for many. Not patient-specific.
- Defined cargoAt least one of LIF, VEGFA and GDF-15.
- Non-invasiveMay facilitate repeat dosing, delivered non-invasively.
- Across the barrierMay carry bioactive molecules across the blood–brain barrier.
AutologousNurOwn
MSC-NTF cells
AllogeneicExosomes
Latest
All news- BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions
- BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman